On January 5, 2022 OPKO Health, Inc. (NASDAQ: OPK) reported that management will be participating in the 40th Annual J.P. Morgan Healthcare Conference being held virtually January 10-13, 2022 (Press release, Opko Health, JAN 5, 2022, View Source [SID1234598234]). Management will be hosting one-on-one meetings with investors and will be participating in a virtual fireside chat on Wednesday, January 12th at 3:00 p.m. Eastern time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The fireside chat will be webcast live and available for replay in the Investors section of OPKO Health’s website and accessible by clicking here.

On January 5, 2021 Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, reported that Anna Protopapas, President and Chief Executive Officer, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:00 p.m. ET (Press release, Mersana Therapeutics, JAN 5, 2022, View Source [SID1234598232]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at www.mersana.com. Archived replays will be available for approximately 30 days following the presentation.

On January 5, 2022 MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, reported that its Chief Executive Officer Michael Castagna, PharmD, will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022 (Press release, Mannkind, JAN 5, 2022, View Source [SID1234598231]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties can access a link to the on demand webcast of the presentation from the Events & Presentations section of the Company’s website at View Source The webcast replay may be accessed at the same location for 14 days.

On January 5, 2022 Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, reported that the company will participate in the following January investor conferences (Press release, Magenta Therapeutics, JAN 5, 2022, View Source [SID1234598230]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

40th Annual J.P. Morgan Healthcare Conference, to be held virtually, on Thursday, January 13th, 2022, at 9:45 a.m. ET, immediately followed by a Q&A session
B. Riley Virtual Oncology Conference, on Friday, January 28th, 2022, at 11:00 a.m. ET
A live webcast of the presentations can be accessed through the Investors & Media section of Magenta’s website at View Source A replay of each webcast will be available on Magenta’s website for 30 days following the events.

On January 5, 2022 Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported that its Chief Executive Officer, Robert E. Hoffman will present at the H.C. Wainwright Bioconnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022 (Press release, Kintara Therapeutics, JAN 5, 2022, View Source [SID1234598227]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available on-demand beginning at 7:00 a.m. ET on Monday, January 10, 2022, and will be available for 90 days.

Register to view the presentation:
View Source